• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
AMCP Market Insights: Impact of the evolving understanding of multiple sclerosis and emerging treatment approaches on managed care.AMCP市场洞察：对多发性硬化症不断演变的认识及新兴治疗方法对管理式医疗的影响
J Manag Care Spec Pharm. 2025 Aug;31(8-a Suppl):S1-S9. doi: 10.18553/jmcp.2025.31.8-a.s1.
2
Uncommon Non-MS Demyelinating Disorders of the Central Nervous System.中枢神经系统罕见的非多发性硬化脱髓鞘疾病
Curr Neurol Neurosci Rep. 2025 Jul 1;25(1):45. doi: 10.1007/s11910-025-01432-8.
3
Azathioprine for people with multiple sclerosis.硫唑嘌呤用于多发性硬化症患者。
Cochrane Database Syst Rev. 2024 Dec 9;12(12):CD015005. doi: 10.1002/14651858.CD015005.pub2.
4
Siponimod for multiple sclerosis.西尼莫德用于多发性硬化症。
Cochrane Database Syst Rev. 2021 Nov 16;11(11):CD013647. doi: 10.1002/14651858.CD013647.pub2.
5
Information provision for people with multiple sclerosis.为多发性硬化症患者提供信息。
Cochrane Database Syst Rev. 2014 Apr 21(4):CD008757. doi: 10.1002/14651858.CD008757.pub2.
6
Pharmacological treatment for memory disorder in multiple sclerosis.多发性硬化症记忆障碍的药物治疗。
Cochrane Database Syst Rev. 2013 Dec 17;2013(12):CD008876. doi: 10.1002/14651858.CD008876.pub3.
7
Treatments for fatigue in multiple sclerosis: a rapid and systematic review.多发性硬化症疲劳的治疗：快速系统评价
Health Technol Assess. 2000;4(27):1-61.
8
Memory rehabilitation for people with multiple sclerosis.针对多发性硬化症患者的记忆康复治疗。
Cochrane Database Syst Rev. 2016 Mar 23;3:CD008754. doi: 10.1002/14651858.CD008754.pub3.
9
A review of laboratory practices for CSF oligoclonal banding and associated tests.脑脊液寡克隆区带及相关检测的实验室操作综述。
Crit Rev Clin Lab Sci. 2025 Aug;62(5):363-385. doi: 10.1080/10408363.2025.2490166. Epub 2025 Apr 20.
10
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.对首次出现提示多发性硬化症临床发作的患者使用疾病修饰药物进行治疗。
Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD012200. doi: 10.1002/14651858.CD012200.pub2.

本文引用的文献

1
Therapeutic advances in multiple sclerosis: Novel therapies (immune checkpoint inhibitors, CAR-T, Anti-CD40L).多发性硬化症的治疗进展：新型疗法（免疫检查点抑制剂、嵌合抗原受体T细胞疗法、抗CD40L）
Neurotherapeutics. 2025 Jul;22(4):e00558. doi: 10.1016/j.neurot.2025.e00558. Epub 2025 Feb 27.
2
Epidemiology of Multiple Sclerosis: Global, Regional, National and Sub-National-Level Estimates and Future Projections.多发性硬化症的流行病学：全球、区域、国家和次国家层面的估计及未来预测。
J Epidemiol Glob Health. 2025 Feb 10;15(1):21. doi: 10.1007/s44197-025-00353-6.
3
Disease-modifying strategies: Targeting protein kinases in multiple sclerosis and other autoimmune disorders.疾病修饰策略：针对多发性硬化症和其他自身免疫性疾病中的蛋白激酶
Autoimmun Rev. 2025 Mar 26;24(4):103754. doi: 10.1016/j.autrev.2025.103754. Epub 2025 Jan 20.
4
A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.布鲁顿酪氨酸激酶抑制剂在多发性硬化症中的综述。
Ther Adv Neurol Disord. 2024 Apr 17;17:17562864241233041. doi: 10.1177/17562864241233041. eCollection 2024.
5
Economic burden of multiple sclerosis in the United States: A systematic literature review.美国多发性硬化症的经济负担：一项系统文献回顾。
J Manag Care Spec Pharm. 2023 Dec;29(12):1354-1368. doi: 10.18553/jmcp.2023.23039. Epub 2023 Nov 17.
6
Population-Based Estimates for the Prevalence of Multiple Sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region.基于人群的美国多发性硬化症患病率估计值：按种族、民族、年龄、性别和地理区域划分。
JAMA Neurol. 2023 Jul 1;80(7):693-701. doi: 10.1001/jamaneurol.2023.1135.
7
Multiple sclerosis progression: time for a new mechanism-driven framework.多发性硬化症的进展：是时候建立一个新的基于机制的框架了。
Lancet Neurol. 2023 Jan;22(1):78-88. doi: 10.1016/S1474-4422(22)00289-7. Epub 2022 Nov 18.
8
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.多发性硬化症高疗效治疗时机：一项回顾性观察队列研究。
Lancet Neurol. 2020 Apr;19(4):307-316. doi: 10.1016/S1474-4422(20)30067-3. Epub 2020 Mar 18.
9
The prevalence of MS in the United States: A population-based estimate using health claims data.美国多发性硬化症的患病率：基于健康保险理赔数据的人群估计
Neurology. 2019 Oct 8;93(15):688. doi: 10.1212/WNL.0000000000007915.
10
How to make value-based health insurance designs more effective? A systematic review and meta-analysis.如何使基于价值的健康保险设计更有效？系统评价和荟萃分析。
Eur J Health Econ. 2019 Aug;20(6):841-856. doi: 10.1007/s10198-019-01046-1. Epub 2019 Mar 28.

AMCP市场洞察：对多发性硬化症不断演变的认识及新兴治疗方法对管理式医疗的影响

AMCP Market Insights: Impact of the evolving understanding of multiple sclerosis and emerging treatment approaches on managed care.

作者信息

Flavin Bridget, Bioc Justin, Evans Janna, Lich Rebecca, O'Shea Timothy, Pourarsalan Hiva

机构信息

Connected Content, Ltd., Boulder, CO.

Devoted Health, Boston, MA.

出版信息

J Manag Care Spec Pharm. 2025 Aug;31(8-a Suppl):S1-S9. doi: 10.18553/jmcp.2025.31.8-a.s1.

DOI:10.18553/jmcp.2025.31.8-a.s1
PMID:40644322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12249916/
Abstract

Multiple sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS) and is associated with significant clinical and economic burden. Advancements in the understanding of the underlying biology of MS have important implications for both diagnosis and treatment. To discuss the impact of continuing developments in MS on managed care, AMCP Market Insights virtually convened an expert panel of managed care stakeholders in December 2024. Key insights from the discussion related to supporting patient needs in MS, advancing understanding of MS, emerging treatments in MS, using real-world evidence in MS coverage decision-making, and addressing continued challenges in MS. Suggested payer best practices in MS also emerged from the discussion.

摘要

多发性硬化症（MS）是一种中枢神经系统（CNS）的免疫介导疾病，会带来重大的临床和经济负担。对MS潜在生物学机制认识的进展对诊断和治疗都具有重要意义。为了探讨MS持续发展对管理式医疗的影响，AMCP市场洞察于2024年12月虚拟召集了一个由管理式医疗利益相关者组成的专家小组。讨论的关键见解涉及满足MS患者需求、加深对MS的理解、MS的新兴治疗方法、在MS保险覆盖决策中使用真实世界证据以及应对MS持续存在的挑战。讨论中还提出了MS中建议的支付方最佳实践。